Related references
Note: Only part of the references are listed.
Article
Oncology
Xin Xie et al.
Summary: The study suggests that combination therapy with engineered oncolytic viruses may serve as a potent immunotherapy strategy for cancer patients, especially those resistant to PD-1/PD-L1 blockade therapy.
TRANSLATIONAL ONCOLOGY
(2022)
Article
Engineering, Biomedical
Jie Chen et al.
Summary: This study explores an intensive tumor immunotherapeutic strategy by combining mannosylated nanovaccines with gene regulated PD-L1 blockade. The mannose modified nanovaccines can effectively co-encapsulate antigen and adjuvant, promoting endocytosis and cross presentation in dendritic cells. However, the limited inhibition of tumor growth by nanovaccines in the immunosuppressed tumor microenvironment can be overcome by combining with gene regulated PD-L1 blockade, leading to significant tumor remission.
BIOACTIVE MATERIALS
(2022)
Review
Medicine, Research & Experimental
Guanglin Cui
Summary: ICB immunotherapy is a promising strategy for colorectal cancer patients, but not all patients respond equally to this treatment. Precision strategies based on individual conditions can improve the therapeutic response.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Multidisciplinary Sciences
Zhaoting Li et al.
Summary: This study reports a method to enhance the effectiveness of anti-tumor immunotherapy by locally depleting tumor-associated macrophages (TAMs) using a hydrogel reservoir. TAMs are depleted by releasing the colony-stimulating factor 1 receptor (CSF1R) inhibitor Pexidartinib and delivering anti-PD-1 antibody-conjugated platelets locally and systemically, effectively inhibiting post-surgery tumor recurrence.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Zhaoting Li et al.
Summary: Blocking cell membrane repair and sustained release of pro-inflammatory substances can enhance tumor cell pyroptosis and boost the anti-tumor immune response.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Ann M. Miller et al.
Summary: The novel immunotherapeutic agent, CMP-001, composed of bacteriophage capsid protein and CpG-A oligodeoxynucleotide, activates pDCs and triggers IFN alpha release, leading to anti-tumor immune effects. In vitro stimulation with CMP-001 showed IFN alpha release and increased percentage of pDCs in peritoneal cells. In vivo studies in murine PC models demonstrated improved survival and enhanced immune response with CMP-001 treatment.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Biophysics
Binod Dhakal et al.
Summary: CAR-T cell therapy has shown unprecedented efficacy in treating multiple myeloma, but still faces challenges such as relapse, drug resistance, and toxic reactions. The development of multi-targeted CAR-T antigens and combinatorial therapies is the direction to overcome these challenges.
BONE MARROW TRANSPLANTATION
(2021)
Review
Immunology
Jezabel Varade et al.
Summary: The immune system is a complex network of cells, soluble factors, membrane molecules, and functionalities, with researchers working to put all pieces of the puzzle together for a more complete understanding. Advances in immunological techniques and the development of new specialized equipment have improved our knowledge of immune-mediated illnesses and how the immune system interacts with other systems. The development of various types of immunotherapies, including vaccines and cellular therapies, is changing the way we approach diseases, particularly cancer.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Zhuting Hu et al.
Summary: Personal neoantigen peptide vaccines induce long-lasting T cell responses in melanoma patients, broadening the spectrum of tumor-specific cytotoxicity and resulting in diverse T cell clones with cytotoxic gene signatures.
Review
Nanoscience & Nanotechnology
Ningqiang Gong et al.
Summary: T-cell-based immunotherapies show promise in treating cancer, but face challenges such as insufficient expansion of transferred T cells and inefficient trafficking into tumors. Nanomaterials offer a solution to enhance T-cell therapy by overcoming physical barriers and modulating tumor microenvironments.
NATURE NANOTECHNOLOGY
(2021)
Review
Oncology
Eryn Blass et al.
Summary: Immunotherapy has revolutionized cancer treatment with the development of immune-checkpoint inhibitors and personalized neoantigen vaccines. These vaccines trigger specific T cell responses against individual patient's tumors, showing promising tumor-specific immunogenicity and antitumor activity.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Hao Li et al.
Summary: A nanoprobe based on NIR-IIb emitting quantum dots was designed to alleviate hypoxia in the tumor microenvironment, enhancing precision and efficacy of radiotherapy, and promoting anti-tumor immune responses.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Dae Won Kim et al.
Summary: This study evaluated the safety and efficacy of ibrutinib plus pembrolizumab in refractory metastatic pMMR CRC, showing that the combination therapy has limited anti-cancer activity in metastatic CRC.
BRITISH JOURNAL OF CANCER
(2021)
Review
Immunology
Morgane Bourhis et al.
Summary: VEGF-A plays a central role in tumor angiogenesis and is also an immunosuppressive factor, modulating immune cells and affecting regulatory T cells. Anti-angiogenic agents targeting VEGF-A/VEGFR can limit tumor-induced immunosuppression and enhance treatment efficacy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Alexandra M. Zaborowski et al.
Summary: Colorectal cancer is the second leading cause of cancer-related death worldwide. Immunooncology has shown promising results in clinical practice and understanding the tumor-immune microenvironment has enabled the development of individualized treatment. By combining chemotherapy and immunotherapies, there is potential for unprecedented disease control, survivorship, and cure rates.
BRITISH JOURNAL OF CANCER
(2021)
Article
Chemistry, Multidisciplinary
Weidong Ni et al.
Summary: Immunotherapy shows promise for tumor treatment, but its clinical effect is limited by tumor immunogenicity and the immunosuppressive microenvironment. Researchers combined metal-organic framework MIL-100 loaded with mitoxantrone (MTO) with photothermal-chemotherapy to enhance immunogenic cell death. The resulting MMH NPs, with dual therapeutic properties and imaging modes, showed high antitumor efficacy and immune effect when co-injected with anti-OX40 antibody in colorectal cancer. This novel combined therapeutic strategy is promising for future tumor therapy.
Article
Chemistry, Multidisciplinary
Yuanji Feng et al.
Summary: This study developed a revolutionary dual gene delivery system loading pshVEGF-A and pshPD-L1 to overcome adaptive resistance to ICB therapy, achieving effective anti-tumor immunotherapy. The strategy eliminates adaptive resistance, achieves tumor vessel normalization, and reprograms the tumor immune microenvironment, contributing to the diversity of immune combination therapy.
Article
Cell Biology
Christian Hotz et al.
Summary: Local administration of mRNA encoding cytokines has shown effective antitumor activity by inducing various immune cell responses, including systemic antigen-specific T cell expansion, increased granzyme B+ T cell infiltration, and formation of immune memory. Combining these mRNAs with immunomodulatory antibodies enhances antitumor responses in both injected and uninjected tumors, improving survival and tumor regression.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Review
Immunology
Mengqin Zhu et al.
Summary: Immunogenic cell death (ICD) is a regulated form of cell death induced by various stresses, which releases DAMPs such as HMGB1, CRT, ATP, and HSPs to produce antitumor immunity. Ionizing radiation (IR) has been shown to induce ICD, with factors like dose, type, and fractionation influencing its induction.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Sijia Ren et al.
Summary: Combining immunotherapy with anti-angiogenesis can transform the tumor microenvironment from immunosuppressive to immune-supportive, increasing the infiltration and activation of immune cells. Therefore, this combination is a promising strategy for cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Yun Wang et al.
Summary: Cancer has a significant impact on the quality of life of humans globally, with the number of patients continuously increasing. The focus of cancer research has shifted towards anti-tumor immunity and the booming development of immunotherapy, leading to a new era in cancer treatment.
CANCER COMMUNICATIONS
(2021)
Article
Engineering, Biomedical
Yingying Hu et al.
Article
Multidisciplinary Sciences
Jiayan Wu et al.
Review
Biochemistry & Molecular Biology
Bernardo L. Rapoport et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2019)
Article
Immunology
Brian C. Miller et al.
Article
Cell Biology
Xingzhe Ma et al.
Review
Immunology
Ana C. Anderson et al.
Review
Immunology
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31
(2013)
Review
Immunology
Ennio De Gregorio et al.
FRONTIERS IN IMMUNOLOGY
(2013)
Review
Immunology
Folkert Steinhagen et al.
